TY - JOUR
T1 - Assessment of tumoral heterogeneity in NSCLC treated with Bevacizumab: a prospective study
AU - Yip, Connie
AU - Tacelli, Nunzia
AU - Remy-Jardin, Martine
AU - Bassett, Paul
AU - Cook, Gary
AU - Landau, David
AU - Goh, Vicky
PY - 2014
Y1 - 2014
N2 - Background: Imaging heterogeneity may reflect biological heterogeneity. Changes in tumoral heterogeneity in NSCLC treated with chemotherapy ± bevacizumab in a prospective study, and their associations with treatment response were assessed. Methods: Forty patients (34 males; mean 60y) with advanced/metastatic NSCLC were treated with platinum-based chemotherapy (Group 1, n=23) or chemotherapy + bevacizumab (Group 2, n=17), and underwent contrast-enhanced CT at baseline, after 1, 3 and 6 cycles of chemotherapy. Radiological response was assessed using both RECIST 1.1 and Crabb criteria. 63 target lesions were selected for heterogeneity analysis generating global and locoregional parameters using first, second, higher-order and model-based methods. Heterogeneity parameters between the two groups were compared using Mann-Whitney U test. Associations between heterogeneity parameters and best radiological response were assessed using univariate and multivariate logistic regressions. A p-value <0.01 was considered significant. Results: More responders were identified using Crabb compared to RECIST criteria: 10 (43%) by Crabb and 8 (35%) by RECIST in Group 1, and 8 (47%) and 7 (41%) in Group 2 respectively. There was no significant difference in the absolute and relative changes in all categories of heterogeneity values between the two groups. Several locoregional heterogeneity parameters were associated with response (Table). Combination of two or more heterogeneity parameters did not improve the predictive value compared to a single parameter. Conclusions: Changes in locoregional heterogeneity parameters were associated with antiangiogenic treatment response in NSCLC.
AB - Background: Imaging heterogeneity may reflect biological heterogeneity. Changes in tumoral heterogeneity in NSCLC treated with chemotherapy ± bevacizumab in a prospective study, and their associations with treatment response were assessed. Methods: Forty patients (34 males; mean 60y) with advanced/metastatic NSCLC were treated with platinum-based chemotherapy (Group 1, n=23) or chemotherapy + bevacizumab (Group 2, n=17), and underwent contrast-enhanced CT at baseline, after 1, 3 and 6 cycles of chemotherapy. Radiological response was assessed using both RECIST 1.1 and Crabb criteria. 63 target lesions were selected for heterogeneity analysis generating global and locoregional parameters using first, second, higher-order and model-based methods. Heterogeneity parameters between the two groups were compared using Mann-Whitney U test. Associations between heterogeneity parameters and best radiological response were assessed using univariate and multivariate logistic regressions. A p-value <0.01 was considered significant. Results: More responders were identified using Crabb compared to RECIST criteria: 10 (43%) by Crabb and 8 (35%) by RECIST in Group 1, and 8 (47%) and 7 (41%) in Group 2 respectively. There was no significant difference in the absolute and relative changes in all categories of heterogeneity values between the two groups. Several locoregional heterogeneity parameters were associated with response (Table). Combination of two or more heterogeneity parameters did not improve the predictive value compared to a single parameter. Conclusions: Changes in locoregional heterogeneity parameters were associated with antiangiogenic treatment response in NSCLC.
M3 - Meeting abstract
SN - 1556-1380
VL - 8
JO - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
IS - 9
ER -